![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Hagar’s GWave Glucose Monitor Designated an FDA Breakthrough Device
Hagar’s GWave Glucose Monitor Designated an FDA Breakthrough Device
November 29, 2021
The FDA has designated Hagar’s GWave noninvasive continuous glucose monitoring system a breakthrough device.
The GWave device is one-third the size of a smartphone and involves less radiofrequency exposure for users than a smartphone, the Israel-based company said.
The device uses radiofrequency waves to measure glucose levels in the blood without the need for a blood sample.
Upcoming Events
-
21Oct